BI
CYTK icon

BVF Inc’s Cytokinetics CYTK Stock Holding History

BVF Inc’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,878,035
Closed -$101M – 70
2020
Q4 		$101M Buy
4,878,035
+1,554,984
+47% +$28.4M 3.99% 8
2020
Q3 		$71.9M Buy
+3,323,051
New +$77.7M 3.92% 8
2020
Q2 		– Sell
-3,938,280
Closed -$46.4M – 59
2020
Q1 		$46.4M Sell
3,938,280
-3,268,178
-45% -$41.7M 4.33% 7
2019
Q4 		$76.5M Buy
7,206,458
+3,040,900
+73% +$31.2M 5.8% 5
2019
Q3 		$47.4M Sell
4,165,558
-1,011,320
-20% -$12.7M 4.98% 5
2019
Q2 		$58.2M Buy
5,176,878
+1,375,061
+36% +$13.3M 6.36% 2
2019
Q1 		$30.8M Sell
3,801,817
-348,822
-8% -$2.56M 3.44% 10
2018
Q4 		$26.2M Sell
4,150,639
-1,036,200
-20% -$7.6M 3.43% 7
2018
Q3 		$51.1M Sell
5,186,839
-364,051
-7% -$2.92M 4.49% 4
2018
Q2 		$46.1M Sell
5,550,890
-170,998
-3% -$1.42M 4.5% 4
2018
Q1 		$41.2M Hold
5,721,888
– – 4.18% 9
2017
Q4 		$46.6M Buy
5,721,888
+4,480,867
+361% +$50.9M 5.62% 6
2017
Q3 		$18M Sell
1,241,021
-749,300
-38% -$10.2M 2.29% 16
2017
Q2 		$24.1M Sell
1,990,321
-2,270,515
-53% -$31.6M 3.74% 11
2017
Q1 		$54.8M Sell
4,260,836
-590,855
-12% -$6.91M 9.31% 3
2016
Q4 		$58.9M Sell
4,851,691
-145,380
-3% -$1.54M 11.84% 2
2016
Q3 		$45.9M Buy
4,997,071
+7,853
+0.2% +$82K 8.64% 3
2016
Q2 		$47.3M Buy
4,989,218
+648,489
+15% +$5.32M 10.09% 2
2016
Q1 		$30.6M Buy
4,340,729
+1,420,101
+49% +$10.4M 7.57% 3
2015
Q4 		$30.6M Buy
2,920,628
+813,639
+39% +$7.98M 5.21% 8
2015
Q3 		$14.1M Hold
2,106,989
– – 2.85% 13
2015
Q2 		$14.2M Hold
2,106,989
– – 2.5% 16
2015
Q1 		$14.3M Sell
2,106,989
-336,111
-14% -$2.51M 2.99% 13
2014
Q4 		$19.6M Buy
2,443,100
+916,100
+60% +$3.93M 3.81% 9
2014
Q3 		$5.38M Buy
1,527,000
+210,000
+16% +$882K 1.12% 18
2014
Q2 		$6.29M Buy
1,317,000
+1,211,295
+1,146% +$7.39M 1% 15
2014
Q1 		$1M Sell
105,705
-2,263,200
-96% -$20.5M 0.16% 27
2013
Q4 		$15.4M Buy
2,368,905
+650,000
+38% +$4.27M 2.69% 10
2013
Q3 		$13M Hold
1,718,905
– – 2.24% 11
2013
Q2 		$19.9M Buy
+1,718,905
New +$13.5M 3.86% 8

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc's CYTK Position: Q1 2021 in Review

BVF Inc sold out of Cytokinetics (CYTK) in Q1 2021, closing a stake of 4,878,035 shares — an estimated $101M sold.

BVF Inc first reported a position in CYTK in Q2 2013 and held it in 30 quarters. The position peaked at $101M in Q4 2020. 192 funds tracked by Wall St. Rank hold CYTK as of Q1 2021.

  • BVF Inc reported no remaining Cytokinetics position as of Q1 2021 after selling out during the quarter.
  • BVF Inc sold 4,878,035 Cytokinetics shares in Q1 2021, an estimated $101M.
  • BVF Inc first reported a position in Cytokinetics in Q2 2013 and held it in 30 quarters.
  • BVF Inc's Cytokinetics position peaked at $101M in Q4 2020.
  • 192 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2021.

Based on BVF Inc's 13F filing for Q1 2021, filed 17 May 2021.